Clinical Trial Search

Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Program Enrollment Rate (%) — 14 Percentage of participants

Primary: Program Enrollment Rate (%) — 6.1 percentage of invitees

Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Change in Hyperglycemia (Percent Change in HbA1c) — -2.2; -1.0 HbA1c percent change

Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl

Primary: Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint — 18.5 percentage of participants

Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin

Primary: Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.91; -1.87 percent (%) glycated hemoglobin — p=0.716

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c

Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants

Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values

Primary: Glucose — -21.55; 1.92 mg/dL

Primary: Percentage of Participants Who Had One or More Adverse Reactions — 5.41; 1.20; 0.98; 0.00 Percentage of Participants

Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830

Primary: Fasting Blood Glucose (FBG) Level at Week 12 Endpoint as Measured by the 8-Point Self-Monitored Blood Glucose (SMBG) Profiles — 6.83; 7.15; 6.84 millimoles per Liter…

Primary: Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% — 22.4; 8.8 percentage of participants — p=0.0499

Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change

Primary: Mean Blood Glucose Concentration After First Day of Treatment — 9.5; 9.4 mmol/L

Primary: Hyperglycemia — 21.5; 33.3; 9.3; 11.7 Percent of Time (%)

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Change in HgbA1c — -1.9 percentage of glycosylated hemoglobin

Primary: Number of Index Dates — 91634; 33238; 28211; 26192 Number of Prescriptions

Primary: Change of HbA1c From Baseline at Week 12 — 2.14; 2.10; 1.95; 2.02 ln(percent) — p=<0.0001

Primary: Maximum Glucose Infusion Rate — 0.3; 2.6; 5.5; 6.8 umol/kg/min — p=<0.05

Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001